PPA-2021-0023 - Remdesivir Overview

<p>By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several</p> <p>vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19.</p> <p>Remdesivir is an antiviral drug approved for emergency use against COVID-19 in several countries, but</p> <p>one of the first clinical trials was inconclusive about the mortality reduction, although the drug showed a</p> <p>reduction in the recovery time of hospitalized patients. Thus, the present investigation revisits the clinical</p> <p>evidence of using remdesivir for COVID-19 treatment, patent status, pharmacology and chemistry. We</p> <p>found 184 families of patents in the Cortellis database, and concerning the clinical evidence, we retrieved</p> <p>14 systematic reviews with meta-analysis involving remdesivir as a treatment for COVID-19, discussing the</p> <p>reduction of adverse events, hospitalization days, mortality rate and the mechanical ventilation period.</p>